Fenwick & West represented Royalty Pharma in the transaction. Geron Corporation (Nasdaq: GERN) announced that Royalty Pharma (Nasdaq: PRRX), a buyer of biopharmaceutical royalties and funder...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Pharmakon Advisors in the transaction. Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Samsara BioCapital in the transaction. Alumis Inc. announced an upsized $259M Series C financing round co-led by existing investor, Foresite Capital, and new...
You must be a Standard 1 Year member to access this content.
